XIDX
KINO
Market cap111mUSD
Nov 12, Last price
1,340.00IDR
Name
Kino Indonesia Tbk PT
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Kino Indonesia Tbk manufactures and markets personal care products, beverages, foods, and pharmaceutical and pet food products in Indonesia and internationally. The company offers various personal care products, including haircare products under the Ellips, Sasha, and Samantha brands; oral care products under the Sasha and Click brands; skin care products under the Ovale and Ristra brands; baby care products under the Sleek Baby brand; decoratives under the Abstract brand; fragrances under the Eskulin brand; feminine hygiene products under the Resik V and Absolute brand names; kids personal care products under the B&B Kids, Eskulin Kids, and Master Kids brands; men's grooming products under the Master brand; air fresheners under the Evergreen brand; hygiene products under the Sleek and Instance Hand Sanitizer brand names; and pet foods under the MAXLife brand. It also provides various beverages, such as remedy drinks under the Cap Kaki Tiga and Larutan Sejuk Segar brands; health drinks under the Cap Panda brand name; energy drinks under the Panther brand; and canned fruit, coconut water, and juices under the Malee brand name. In addition, the company offers confectionary products comprising candies under the Kino Candy, Oplozz, Frenta Candy, and Chew Chew Ball brand names; snacks under the Kino Naster and Snack It brands; and powdered drink under the Segar Sari brand. Further, it provides pharmaceutical products, such as herbal cough medicines, balms, headache medicines, and ringworm medicines under the Cap Kaki Tiga and Q-Life brands; and herbal products under the Dua Putri Dewi brand. The company was formerly known as PT Kinocare Era Kosmetindo. The company was incorporated in 1999 and is headquartered in Tangerang, Indonesia. PT Kino Indonesia Tbk is a subsidiary of PT Kino Investindo.
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||